Biotech · Public company · Lexington, MA, US
Curis Inc
Ticker CRIS · SEC CIK 0001108205
Track this companyFree. Adds Curis Inc to your Dealase workspace and tells you when its record changes.
Clinical trials124 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline13
- CUDC-907Phase 2 · Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc AlterationsClinicalTrials.gov · fetched Nov 12, 2026
- EmavusertibPhase 2 · Relapsed Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- EmavusertibPhase 2 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- EmavusertibPhase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- IbrutinibPhase 2 · Relapsed Hematologic MalignancyClinicalTrials.gov · fetched Nov 12, 2026
- VenetoclaxPhase 2 · Acute Myelogenous LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- ZanubrutinibPhase 2 · Chronic Lymphocytic LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CA-170Phase 1 · Advanced Solid Tumors or LymphomasClinicalTrials.gov · fetched Nov 12, 2026
- CI-8993Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- CUDC-907Phase 1 · Triple-Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- fimepinostatPhase 1 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- RituximabPhase 1 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- venetoclaxPhase 1 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials12
- A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesPHASE2 · RECRUITING · started Apr 23, 2026ClinicalTrials.gov NCT07271667 · fetched Nov 12, 2026
- Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract CancerPHASE1 · RECRUITING · started Mar 27, 2026ClinicalTrials.gov NCT07107750 · fetched Nov 12, 2026
- CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal CancerPHASE1 · RECRUITING · started Jun 2, 2023ClinicalTrials.gov NCT05187182 · fetched Nov 12, 2026
- Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor MalignanciesPHASE1 · COMPLETED · started Sep 22, 2020ClinicalTrials.gov NCT04475523 · fetched Nov 12, 2026
- Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)PHASE1_PHASE2 · SUSPENDED · started Jul 6, 2020ClinicalTrials.gov NCT04278768 · fetched Nov 12, 2026
- Fimepinostat in Treating Brain Tumors in Children and Young AdultsEARLY_PHASE1 · COMPLETED · started Aug 7, 2019ClinicalTrials.gov NCT03893487 · fetched Nov 12, 2026
- CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)PHASE1_PHASE2 · RECRUITING · started Dec 28, 2017ClinicalTrials.gov NCT03328078 · fetched Nov 12, 2026
- Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaPHASE1 · COMPLETED · started Oct 1, 2016ClinicalTrials.gov NCT02909777 · fetched Nov 12, 2026
- Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC AlterationsPHASE2 · COMPLETED · started Jul 1, 2016ClinicalTrials.gov NCT02674750 · fetched Nov 12, 2026
- A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and LymphomasPHASE1 · COMPLETED · started May 1, 2016ClinicalTrials.gov NCT02812875 · fetched Nov 12, 2026
- Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid TumorsPHASE1 · COMPLETED · started Nov 1, 2014ClinicalTrials.gov NCT02307240 · fetched Nov 12, 2026
- Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaPHASE1 · COMPLETED · started Dec 1, 2012ClinicalTrials.gov NCT01742988 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 19, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 424B4 · 424B4SEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- S-1 · S-1SEC EDGAR · filed Aug 10, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 2, 2026 · fetched Nov 12, 2026
- 8-K/A · 8-K/ASEC EDGAR · filed Jul 1, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 1, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 22, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026